These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 19662651)

  • 1. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients.
    Lu J; Fan T; Zhao Q; Zeng W; Zaslavsky E; Chen JJ; Frohman MA; Golightly MG; Madajewicz S; Chen WT
    Int J Cancer; 2010 Feb; 126(3):669-83. PubMed ID: 19662651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.
    Aktas B; Tewes M; Fehm T; Hauch S; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(4):R46. PubMed ID: 19589136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of circulating tumor cells in the context of treatment: prognostic value in breast cancer.
    Serrano MJ; Sánchez-Rovira P; Delgado-Rodriguez M; Gaforio JJ
    Cancer Biol Ther; 2009 Apr; 8(8):671-5. PubMed ID: 19242121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy using the nanotube-CTC-chip: capture of invasive CTCs with high purity using preferential adherence in breast cancer patients.
    Loeian MS; Mehdi Aghaei S; Farhadi F; Rai V; Yang HW; Johnson MD; Aqil F; Mandadi M; Rai SN; Panchapakesan B
    Lab Chip; 2019 Jun; 19(11):1899-1915. PubMed ID: 31049504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
    Botteri E; Sandri MT; Bagnardi V; Munzone E; Zorzino L; Rotmensz N; Casadio C; Cassatella MC; Esposito A; Curigliano G; Salvatici M; Verri E; Adamoli L; Goldhirsch A; Nolè F
    Breast Cancer Res Treat; 2010 Jul; 122(1):211-7. PubMed ID: 19967556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer.
    Lee CH; Hsieh JC; Wu TM; Yeh TS; Wang HM; Lin YC; Chen JS; Lee CL; Huang WK; Hung TM; Yen TT; Chan SC; Chou WC; Kuan FC; Hu CC; Chang PH
    BMC Cancer; 2019 Dec; 19(1):1167. PubMed ID: 31791269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection and clinical significance of circulating tumor cells in peripheral blood of breast cancer patients].
    Cai QQ; Huang HQ; Lin TX; Jiang WQ
    Ai Zheng; 2005 Jul; 24(7):837-41. PubMed ID: 16004811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vita-Assay™ Method of Enrichment and Identification of Circulating Cancer Cells/Circulating Tumor Cells (CTCs).
    Tulley S; Zhao Q; Dong H; Pearl ML; Chen WT
    Methods Mol Biol; 2016; 1406():107-19. PubMed ID: 26820949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells in early breast cancer: A connection with vascular invasion.
    Maltoni R; Fici P; Amadori D; Gallerani G; Cocchi C; Zoli M; Rocca A; Cecconetto L; Folli S; Scarpi E; Serra P; Fabbri F
    Cancer Lett; 2015 Oct; 367(1):43-8. PubMed ID: 26184997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer.
    Gruber I; Landenberger N; Staebler A; Hahn M; Wallwiener D; Fehm T
    Anticancer Res; 2013 May; 33(5):2233-8. PubMed ID: 23645781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.
    Premasekharan G; Gilbert E; Okimoto RA; Hamirani A; Lindquist KJ; Ngo VT; Roy R; Hough J; Edwards M; Paz R; Foye A; Sood R; Copren KA; Gubens M; Small EJ; Bivona TG; Collisson EA; Friedlander TW; Paris PL
    Cancer Lett; 2016 Sep; 380(1):144-52. PubMed ID: 27343980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients.
    Soria JC; Gauthier LR; Raymond E; Granotier C; Morat L; Armand JP; Boussin FD; Sabatier L
    Clin Cancer Res; 1999 May; 5(5):971-5. PubMed ID: 10353728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the diagnostic value of circulating tumor cells with CytoSorter
    Jin L; Zhao W; Zhang J; Chen W; Xie T; Wang L; Fan W; Xie S; Shen J; Zheng H; Hu W; Wei Q; Dong M; Wang Q; Shen J; Liu Y
    Cancer Med; 2020 Mar; 9(5):1638-1647. PubMed ID: 31908156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
    Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.
    Vetter M; Landin J; Szczerba BM; Castro-Giner F; Gkountela S; Donato C; Krol I; Scherrer R; Balmelli C; Malinovska A; Zippelius A; Kurzeder C; Heinzelmann-Schwarz V; Weber WP; Rochlitz C; Aceto N
    Breast Cancer Res; 2018 Nov; 20(1):141. PubMed ID: 30458879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of circulating tumor cells in metastatic breast cancer patients.
    Sanislo L; Vertakova-Krakovska B; Kuliffay P; Brtko J; Galbava A; Galbavy S
    Endocr Regul; 2011 Jul; 45(3):113-24. PubMed ID: 21793623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance.
    Zhou J; Zhu X; Wu S; Guo J; Zhang K; Xu C; Chen H; Jin Y; Sun Y; Zheng S; Chen Y
    Cancer Biol Med; 2020 Feb; 17(1):169-180. PubMed ID: 32296584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.